Endologix (NASDAQ:ELGX) updated its FY18 earnings guidance on Thursday. The company provided earnings per share guidance of ($0.91-0.87) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($1.10). The company issued revenue guidance of $150-155 million, compared to the consensus revenue estimate of $151.75 million.Endologix also updated its FY 2018 guidance to $-0.91–0.87 EPS.
A number of research firms have recently issued reports on ELGX. Oppenheimer reissued a hold rating on shares of Endologix in a report on Wednesday, October 3rd. Piper Jaffray Companies lowered Endologix from an overweight rating to a neutral rating in a report on Friday, August 10th. BMO Capital Markets reissued a hold rating and issued a $4.00 target price (down previously from $6.50) on shares of Endologix in a report on Friday, August 10th. ValuEngine raised Endologix from a sell rating to a hold rating in a report on Thursday, August 2nd. Finally, BidaskClub lowered Endologix from a strong-buy rating to a buy rating in a report on Wednesday, July 25th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $3.86.
ELGX stock traded up $0.04 on Thursday, reaching $1.26. 1,032,020 shares of the company’s stock were exchanged, compared to its average volume of 694,297. Endologix has a twelve month low of $1.09 and a twelve month high of $6.72. The firm has a market capitalization of $103.34 million and a PE ratio of -2.63. The company has a debt-to-equity ratio of 5.37, a current ratio of 1.90 and a quick ratio of 1.20.
Endologix (NASDAQ:ELGX) last announced its quarterly earnings data on Thursday, August 9th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.18). Endologix had a negative return on equity of 69.06% and a negative net margin of 40.92%. The firm had revenue of $44.70 million for the quarter, compared to analyst estimates of $44.43 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. Endologix’s quarterly revenue was down 8.0% on a year-over-year basis. Equities research analysts expect that Endologix will post -0.86 earnings per share for the current fiscal year.
In other Endologix news, CFO Vaseem Mahboob acquired 30,000 shares of the company’s stock in a transaction that occurred on Thursday, August 16th. The shares were purchased at an average price of $2.43 per share, with a total value of $72,900.00. Following the completion of the acquisition, the chief financial officer now directly owns 146,812 shares of the company’s stock, valued at approximately $356,753.16. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.90% of the company’s stock.
Endologix Company Profile
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
See Also: Fiduciary
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.